{
    "clinical_study": {
        "@rank": "50348", 
        "arm_group": [
            {
                "arm_group_label": "Eculizumab", 
                "arm_group_type": "Experimental", 
                "description": "Biological/Vaccine:  Eculizumab Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks 5-26"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo contains the same buffer components without the active ingredient"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if eculizumab is safe and effective for the\n      treatment of refractory generalized Myasthenia Gravis."
        }, 
        "brief_title": "Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractory Generalized Myasthenia Gravis", 
        "condition_browse": {
            "mesh_term": [
                "Myasthenia Gravis", 
                "Muscle Weakness"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Male or female patients \u226518 years old\n\n          -  Diagnosis of MG made by the following tests:\n\n               1. Positive serologic test for anti-AChR Abs as confirmed at screening, and\n\n               2. One of the following:\n\n                    1. History of abnormal neuromuscular transmission test demonstrated by\n                       single-fiber electromyography (SFEMG) or repetitive nerve stimulation, or\n\n                    2. History of positive anticholinesterase test, e.g. edrophonium chloride\n                       test, or\n\n                    3. Subject has demonstrated improvement in MG signs on oral cholinesterase\n                       inhibitors, as assessed by the treating physician.\n\n          -  MGFA Clinical Classification Class II to IV at screening.\n\n          -  MG-ADL total score must be \u22656 at screening\n\n          -  Subjects who have:\n\n               1. Failed treatment with at least two immunosuppressive agents. Or,\n\n               2. Failed treatment with at least one immunosuppressive agent and require chronic\n                  plasma exchange or IVIg\n\n        Key Exclusion Criteria:\n\n          -  History of thymoma or other neoplasms of the thymus\n\n          -  History of thymectomy within 12 months prior to screening\n\n          -  MGFA Class I or MG crisis at screening (MGFA Class V)\n\n          -  Use of rituximab within 6 months prior to screening\n\n          -  Use of IVIg or PE within 4 weeks prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997229", 
            "org_study_id": "ECU-MG-301", 
            "secondary_id": "2013-003589-15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Eculizumab", 
                "description": "Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks 5-26", 
                "intervention_name": "Eculizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myasthenia Gravis", 
            "Eculizumab", 
            "safety", 
            "efficacy"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93711"
                    }, 
                    "name": "University of California San Francisco-Fresno"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "University of California-Irvine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34205"
                    }, 
                    "name": "University of South Florida"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32209"
                    }, 
                    "name": "University of Florida Health Science Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa College of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01805"
                    }, 
                    "name": "Lahey Clinic Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Lockport", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14094"
                    }, 
                    "name": "Buffalo General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Hospital For Special Surgery/New York Presbyterian Hospital Cornell Campus"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina at Chapel Hill"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc"
                }, 
                "facility": {
                    "address": {
                        "city": "Cordova", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38018"
                    }, 
                    "name": "Wesley Neurology Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Methodist Neurological Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "University of Texas Health Science Center at San Antonio"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3A 2B4"
                    }, 
                    "name": "Montreal Neurological Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Hanamaki-shi", 
                        "country": "Japan", 
                        "state": "Iwate-Ken", 
                        "zip": "025-0075"
                    }, 
                    "name": "Hanamaki General Hospitals"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals, Inc."
                }, 
                "facility": {
                    "address": {
                        "city": "Higashisonogi-gun", 
                        "country": "Japan", 
                        "state": "Nagasaki-Ken", 
                        "zip": "859-3615"
                    }, 
                    "name": "NHO Nagasaki Kawatana Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Japan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)", 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharmaceuticals"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Brazil: National Health Surveillance Agency", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Canada: Health Canada", 
                "Denmark: Danish Health and Medicines Authority", 
                "Finland: Finnish Medicines Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Greece: National Organization of Medicines", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "Turkey: Turkish Pharmaceuticals and Medical Devices Institution", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "change from baseline in MG-ADL total score @Week 26 for eculizumab as compared to placebo.", 
            "measure": "change in total MG-ADL score", 
            "safety_issue": "No", 
            "time_frame": "End of study (Week 26/ Visit 17)"
        }, 
        "reference": {
            "PMID": "23512355", 
            "citation": "Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997229"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events, vital signs, laboratory assessments, Physical Exams, and ECGs.", 
            "measure": "Overall safety and tolerability of eculizumab", 
            "safety_issue": "Yes", 
            "time_frame": "end of study (week 26)"
        }, 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}